Tarpon Biosystems, founded in 2006, focuses on addressing critical needs in the biopharmaceutical industry by reducing production costs and adding flexibility in purification operations. The company has developed BioSMB™, a proprietary, disposable-based technology that enables the use of highly efficient, low-cost industrial purification processes in the biomanufacturing environment. This innovative downstream processing solution aims to bring unparalleled efficiency, flexibility, and practicality to bioprocess while reducing the cost of therapeutics.
With expertise in biomanufacturing, Tarpon Biosystems is committed to making new technology easy to implement by partnering with customers and providing a complete line of support services and tools. The company aims to alleviate legacy manufacturing bottlenecks and create a true facility of the future that employs fully disposable process trains.
Tarpon Biosystems operates in the biopharma, biotechnology, health care, and manufacturing industries. As of now, there is no public information available regarding the company's last investment and investors.
